Contrast agents gain approval in France:
This article was originally published in Clinica
The following contrast agents have gained pre-marketing approval in France: Bracco-Byk Gulden's Iomeron (iomeprol) 350 in 150 ml flask; and Mallinckrodt Medical's Octreoscan.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.